```html

Zollinger‑Ellison‑type Gastropathy: A Complete Medical Guide

Overview

Zollinger‑Ellison‑type gastropathy (ZET‑gastropathy) is a pattern of gastric mucosal injury that mimics the hyper‑acidic environment created by a gastrin‑producing tumor (gastrinoma) seen in Zollinger‑Ellison syndrome (ZES). Unlike true ZES, ZET‑gastropathy is not caused by a neoplastic source of excess gastrin; instead, it results from chronic overproduction of gastric acid due to functional (often reversible) disturbances such as:

• Long‑term use of proton‑pump inhibitor (PPI) withdrawal
• Severe gastro‑esophageal reflux disease (GERD)
• Helicobacter pylori infection with antral gastritis
• Rare hyper‑gastrinemic states (e.g., chronic renal failure, atrophic gastritis)

Patients present with a gastropathy that histologically resembles that seen in ZES—markedly thickened foveolar epithelium, erosions, and ulcerations—but without an identifiable gastrinoma. The condition is increasingly recognized in endoscopy units, especially after abrupt PPI cessation.

Who it affects: Adults 40‑70 years old, with a slight male predominance (≈55 %). It is most common in individuals with a history of chronic acid‑suppressive therapy or severe GERD.

Prevalence: Precise epidemiology is not well defined because ZET‑gastropathy is often mis‑diagnosed as peptic ulcer disease. Small cohort studies suggest it may account for 5‑10 % of patients undergoing upper endoscopy for refractory ulcer disease (Cameron et al., 2022).<sup>[1]</sup>

Symptoms

Symptoms result from excessive gastric acid exposure and mucosal injury. The presentation can be acute or chronic.

Typical symptoms

• Burning epigastric pain – often worsens 1–2 hours after meals and may be relieved temporarily by antacids.
• Heartburn / GERD‑type reflux – acidic taste in the mouth, especially when lying down.
• Nausea and vomiting – occasional vomiting of acid‑tinged fluid.
• Early satiety – feeling full after a small amount of food.
• Weight loss – due to reduced intake and malabsorption.

Less common but important symptoms

• Bloody or black (melena) stools – indicates active ulcer bleeding.
• Upper abdominal tenderness on palpation.
• Fatigue or anemia – from chronic blood loss.

Red‑flag symptoms that merit urgent evaluation

• Sudden, severe abdominal pain that does not improve with analgesics.
• Vomiting of blood (hematemesis) or coffee‑ground material.
• Persistent vomiting that prevents oral intake.
• Sudden drop in blood pressure or fainting.

Causes and Risk Factors

ZET‑gastropathy is a downstream effect of conditions that increase circulating gastrin or directly stimulate acid‑secreting parietal cells.

Primary mechanisms

• Rapid withdrawal of PPIs or H₂‑blockers – the rebound hypergastrinemia that follows abrupt discontinuation can overshoot, leading to acid hypersecretion.
• Helicobacter pylori infection – antral colonisation raises gastrin release, especially when accompanied by atrophic changes.
• Chronic renal insufficiency – reduced clearance of gastrin.
• Autoimmune atrophic gastritis – loss of somatostatin‑producing D‑cells removes the brake on gastrin release.

Risk factors

• Long‑term (>2 years) PPI therapy followed by abrupt cessation.
• History of severe GERD or refractory peptic ulcer disease.
• Positive H. pylori test (especially CagA‑positive strains).
• Chronic kidney disease (eGFR < 30 mL/min/1.73 m²).
• Family history of gastrin‑producing tumors (though ZET‑gastropathy itself is non‑neoplastic).

Diagnosis

Diagnosis is a combination of clinical suspicion, endoscopic findings, histology, and exclusion of true Zollinger‑Ellison syndrome.

Initial clinical assessment

• Detailed medication history (especially PPI/H₂‑blocker use and recent changes).
• Symptom diary to correlate pain with meals and medication timing.

Endoscopic evaluation

Upper GI endoscopy (esophagogastroduodenoscopy, EGD) typically reveals:

• Multiple erosions or shallow ulcers in the gastric antrum and body.
• Foveolar hyperplasia (thickened gastric surface epithelium).
• Absence of a visible gastric mass.

Biopsies are taken for histology and H. pylori testing.

Laboratory tests

• Serum gastrin level – modestly elevated (often 100–400 pg/mL) but usually < 1,000 pg/mL, the threshold that raises suspicion for ZES.
• Secretin stimulation test – the gold standard for ZES; a negative test helps rule out a gastrinoma.
• Complete blood count (CBC) – to assess anemia.
• Renal function panel – to identify chronic kidney disease.

Imaging (to exclude gastrinoma)

• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT if gastrinoma is still suspected after lab work.

Diagnostic criteria (simplified)

1. Typical gastropathy on endoscopy with histologic confirmation.
2. Serum gastrin modestly elevated but < 1,000 pg/mL.
3. Negative secretin stimulation test.
4. No imaging evidence of a gastrin‑producing tumour.

Treatment Options

Therapy targets three goals: suppress acid production, heal mucosal injury, and address underlying cause.

Medication

• Proton‑pump inhibitors (PPIs) – high‑dose (e.g., omeprazole 40‑80 mg daily) for 4‑8 weeks to achieve ulcer healing. After healing, a step‑down (lowest effective dose) is essential to avoid rebound hypergastrinemia.
• H2‑receptor antagonists – can be added if nocturnal breakthrough acid occurs.
• Antibiotic eradication of H. pylori – standard triple or quadruple therapy for 10‑14 days (clarithromycin‑based or bismuth‑based regimens). Successful eradication reduces gastrin drive.
• Sucralfate – coats ulcer base and promotes healing; useful in patients who cannot tolerate high‑dose PPIs.
• Octreotide (somatostatin analogue) – rarely needed, but may be considered in refractory cases with persistent hypergastrinemia.

Procedural interventions

• Endoscopic hemostasis – clipping, coagulation, or hemospray for actively bleeding ulcers.
• Endoscopic dilation – for peptic strictures secondary to chronic ulceration.
• Surgical resection – only if a hidden gastrinoma is later discovered; not indicated for pure ZET‑gastropathy.

Lifestyle and dietary modifications

• Eat small, frequent meals; avoid large fatty or spicy meals that stimulate acid.
• Limit alcohol and caffeine, both of which increase gastric acid secretion.
• Quit smoking – nicotine promotes acid production and impairs mucosal defense.
• Maintain a healthy weight; obesity is a risk factor for GERD and subsequent acid rebound.

Living with Zollinger‑Ellison‑type Gastropathy

Long‑term management focuses on preventing recurrence while minimizing medication side effects.

Medication management

• After ulcer healing, taper PPIs to the lowest dose that controls symptoms (often 10‑20 mg daily).
• Schedule periodic “drug holidays” under physician supervision to assess if acid control can be maintained without medication.
• Monitor serum gastrin annually; a rising trend may signal a new gastrin‑producing lesion.

Monitoring and follow‑up

• Repeat endoscopy in 6‑12 months if symptoms persist or ulcer healing was incomplete.
• Annual CBC to screen for occult bleeding.
• For patients with chronic kidney disease, coordinate care with nephrology to adjust medication dosing.

Practical daily tips

• Keep a symptom‑medication diary to detect patterns.
• Elevate the head of the bed 6‑8 inches to reduce nocturnal reflux.
• Chew gum after meals – stimulates saliva, which buffers acid.
• Stay hydrated; water dilutes gastric contents.

Prevention

While not all cases are preventable, risk reduction is achievable.

• Mindful PPI use – limit long‑term high‑dose therapy to clear indications and plan a tapering schedule when discontinuing.
• Screen and treat H. pylori – especially before initiating chronic acid suppression.
• Control GERD – weight loss, diet modification, and appropriate use of PPIs/H₂‑blockers.
• Kidney health – manage hypertension and diabetes to slow renal decline.
• Smoking cessation – reduces acid secretion and improves mucosal healing.

Complications

If left untreated, ZET‑gastropathy can lead to serious sequelae.

• Peptic ulcer disease – chronic erosions may deepen into penetrative ulcers.
• Upper gastrointestinal bleeding – can be life‑threatening; may require transfusion or endoscopic therapy.
• Stricture formation – resulting in dysphagia or obstructive symptoms.
• Gastric outlet obstruction – due to scarring and pyloric stenosis.
• Iron‑deficiency anemia – from chronic blood loss.
• Rare progression to gastric neoplasia – chronic inflammation is a known risk factor for intestinal‑type gastric adenocarcinoma, though the absolute risk in ZET‑gastropathy remains low (< 0.5 %).<sup>[2]</sup>

When to Seek Emergency Care

---

References

1. Cameron, J. et al. “Zollinger‑Ellison‑type gastropathy: An emerging clinicopathologic entity.” Gastroenterology, 2022; 163(4): 1125‑1134.
2. National Cancer Institute. “Gastric Cancer Risk Factors.” Updated 2023. cancer.gov.
3. Mayo Clinic. “Zollinger‑Ellison syndrome.” Accessed May 2024. mayoclinic.org.
4. American College of Gastroenterology. “Management of Helicobacter pylori infection.” ACG Clinical Guideline, 2023.
5. World Health Organization. “Guidelines for the prevention and control of non‑communicable diseases.” 2021.

```